Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday

Syros Pharmaceuticals (NASDAQ:SYRS) will be releasing its earnings data before the market opens on Tuesday, May 14th. Analysts expect Syros Pharmaceuticals to post earnings of ($0.89) per share for the quarter.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.04. Syros Pharmaceuticals had a negative return on equity of 227.91% and a negative net margin of 1,656.34%. The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $2.40 million. On average, analysts expect Syros Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syros Pharmaceuticals Price Performance

Shares of NASDAQ SYRS opened at $5.15 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 3.95 and a debt-to-equity ratio of 2.07. Syros Pharmaceuticals has a fifty-two week low of $2.09 and a fifty-two week high of $8.17. The business has a 50 day moving average price of $5.76 and a two-hundred day moving average price of $5.45. The firm has a market cap of $137.66 million, a PE ratio of -0.89 and a beta of 1.75.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SYRS. StockNews.com lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 17th. Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Syros Pharmaceuticals in a report on Monday, April 1st.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.